InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
0.00%
)
US TECH 100
17,027.20
(
0.99%
)
Dow Jones
37,903.29
(
0.00%
)
Brent Oil
83.73
(
0.22%
)
Bitcoin
58,633.17
(
0.68%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 82
Posts 12424
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Tuesday, 12/07/2010 2:42:35 PM

Tuesday, December 07, 2010 2:42:35 PM

Post# of 80490
Onyx said, due to strong phase II data for carfilzomib, it expects that it's drug will in the market one year earlier than expected.

Onyx /quotes/comstock/15*!onxx/quotes/nls/onxx (ONXX 33.57, +4.23, +14.42%) has been testing carfilzomib for the treatment of multiple myeloma, a type of blood cancer. Onyx said that based on the strong Phase II data, it hopes to be able to file for possible accelerated approval with U.S. regulators as early as mid-2011.

Accelerated approval would mean the product could be out on the market at least one year earlier than normally expected.

It can happen...
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up